IMUX expects pivotal phase III vidofludimus calcium data by year-end
Vidofludimus calcium is advancing through pivotal phase III trials in relapsing MS. The program targets key data readouts by year-end and aims for an NDA submission next year.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.